Pre-Conference Workshop Day
Tuesday, July 30 2024
7:30 am
Check-in & Light Breakfast
Workshop A
8:30 am Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy
Synopsis
As we see more innovation to improve targeting approaches across radio conjugates, the design and development of these molecules is no easy ride. With the aim to balance the specificity, efficacy and radiation exposure to non-targeted tissues, this workshop will critically analyze current targeting approaches.
Hear the latest content and dive into discussions on:
• Delving into pharmacokinetic profiles to understand the parameters that dictates a successful radiopharmaceutical
• Uncovering novel bispecific antibodies to target tissues
• Exploring small molecules: substrate analogues and metabolic tracers for targeting
• Evaluating novel peptide ligands
• Considerations for use in varying beta and alpha emitting isotopes
• Comparing different approaches
• Regulatory challenges for new modalities
Workshop D
8:30 am Addressing the Silos to Move Toward an Integrated Approach With Enhanced Trial Design & Execution Across Radiopharmaceutical Research
Synopsis
Radiopharmaceutical development is driven by collaboration between radio pharmacists, nuclear medicine specialists, chemists, bioengineers and more. While the industry is on the brink of expanding their horizons to even more unmet medical needs, there is a clear bottleneck in the blend of expertise required to design and run a radiopharmaceutical trial.
Learn perspectives from key clinicians and industry players to learn exactly how the field can operationalize clinical research:
- Identify the bottlenecks to uncover areas to be streamlined
- Explore specialized training solutions
- Integrating the sponsor and the clinicians toward a unified end goal
- Maintaining a patient-centric approach in trial design
- Enhancing integration of nuclear medicine in the clinic
- Understanding new challenges specific to alpha emitters
10:30 am
Morning Break & Networking
Workshop B
11:00 am Maximizing Combination Approaches to Transform Safety & Efficacy Profiles
Synopsis
Garnering excitement across the precision oncology field, combination-based approaches have proven to expand therapeutic efficacy and optimize treatment outcomes. It is no surprise that the radiopharmaceuticals space is following full steam ahead, as we see early clinical data and uncover more about the preclinical learnings in dual therapies.
Discover more on combinations:
• Explore immune checkpoint modulators with radioligands
• Utilize DNA repair inhibitors such as PARP, ATM/ATR and DNA methyltransferases
• Uncovering immune profiles stimulated by alpha and beta emission
• Understand challenges with increased complexity of treatment regimens
Workshop E
11:00 am Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes
Synopsis
Dosimetry data gives precise insight into radiation dose delivery and tissue penetration, but there is still work to be done to unlock the true potential of this tool. From understanding dose-response relationships and establishing safe dose limits for normal organs to overcoming logistical hurdles in clinical implementation. There is ongoing research and development efforts to improve dosimetry models, enhance imaging techniques, and gather more data on radiopharmaceutical pharmacokinetics and biodistribution – but how can this truly be implemented in the clinic?
Partake in this workshop to accelerate the field of dosimetry and hear insights on:
- Revealing current regulatory perspectives and guidelines and identifying the need for future clarification
- Reaching new definitions to overcome external beam challenges
- Uncovering new analytical tools
- Addressing differences in the image analysis
- Machine learning and AI to enhance dosimetry insights
- Alpha vs. beta dosimetry of therapeutic radiopharmaceuticals
- Relative biological effect (RBE) and alpha dosimetry
- Role of alpha dosimetry in the design of clinical trials
1:00 pm
Lunch Break & Networking
Workshop C
2:00 pm Refining Your Drug Candidates Through Pre-Clinical Lead Optimization to Ensure Translational Success – Dive into the Discussions
Synopsis
Refining potential drug targets before they advance to costly and time-intensive clinical trials is important. With more organizations working across novel targeting agents, further radioisotopes, new linkers and chelators – lead optimization is integral for translational success leading to the development of safer and more effective drugs for patients.
Join this interactive workshop to hear more on:
- Uncovering preclinical evaluation processes to select efficiently good radiolabeled molecules
- Assessing the addition of linkers and choice of chelating agent
- Screening combinations of radiometal complexes, linker and conjugation function
- Novel platforms to design new molecules
- Enhancing PKPD, binding affinity and biodistribution
- Assessing and mitigating your translational risk
Workshop F
2:00 pm A Personalized Future: Tailoring the Optimal Patient Care
Synopsis
Explore the potential of personalized approach in radiopharmaceutical therapies and the obstacles to its broader adoption. With the unique opportunity to take advantage of dosimetry data, the industry is exploring how the next TRPs can be individually adapted.
Explore future perspectives for tailored treatments by joining this workshop:
- Use dosimetry to guide personalized treatment and dosing approaches
- Leverage artificial intelligence and machine learning to further enhance radiopharmaceuticals’ potential for predictive modelling, image analysis, and treatment optimization
- Advance personalization with combination treatments
- Gain regulatory perspectives